API Heparin Market: Introduction
- Heparin is an anticoagulant that is primarily used to prevent and treat venous thrombosis, pulmonary embolism, and other conditions of blood clotting
- Heparin is the foremost clinical anticoagulant with more than 500 million doses consumed worldwide every year. Heparin and related molecules exhibit a large number of newly discovered biological activities with optimum therapeutic potential. Advantages of heparin, such as immediate onset of action, short half-life, simple laboratory monitoring, ability to get reversed (protamine), and low cost, have led to its wide usage.
- Low molecular weight heparin (LMWH) is derived from unfractionated heparin with an average molecular weight of less than 8,000 Da. Currently, LMWH is utilized in the management of arterial and venous thrombosis. LMWH has fewer side-effects as compared to unfractionated heparin, which involves less risk of heparin-induced osteopenia (HIO) and heparin-induced thrombocytopenia (HIT).
Request Brochure for Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=78699
Key Drivers and Restraints of Global API Heparin Market
- Coagulation disorders such as venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, cause around 1.2 million deaths across the world each year. According to the CDC, an estimated 500,000 to 900,000 people are affected by VTE in the U.S. each year. Moreover, the number of deaths due to VTE in Europe is higher than deaths caused by AIDS, breast and prostate cancers, and highway accidents, collectively.
- The Chinese adulterated heparin issue in 2008 drastically affected the import of crude and API heparin in the U.S. and Europe from China, leading to a demand-supply gap in the last few years. Consequently, several slaughterhouse owners have started venturing into heparin processing business to curtail the demand-supply gap and reduce the overall cost of finished goods. For instance, in November 2014, Germany-based meat company Tönnies entered the heparin processing business by acquiring heparin API maker Pharma Action in Germany. Representatives of Pharma Action stated that the company is expected to produce 30 metric tons of heparin in the near future, which accounts for 60% of demand for traceable heparin raw material in Europe.
- Prevailing limitation in reversing the activity of naturally-derived low molecular weight heparin (LMWH) in case of overdose could lead to excessive bleeding and harm to patients with poor kidney function. In 2014, researchers at the Rensselaer Polytechnic Institute and the University of North Carolina (UNC) developed a synthetic form of LMWH that is safe and can be reversed in activity using an antidote called protamine. According to the research, this synthetic heparin is safer and inexpensive, as compared to the currently available heparin that is derived from animals.
Request for Analysis of COVID19 Impact on API Heparin Market –
https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=78699
North America to Lead Global API Heparin Market
- In terms of region, the global API heparin market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Europe are likely to account for a major share of the global API heparin market during the forecast period. North America is estimated to lead the global market for heparin owing to a rise in the geriatric population, increase in incidences of cancer and its associated clotting disorders, and a surge in the number of coagulation tests during pregnancy. Rise in the number of passengers in long-duration flights and prolonged immobility due to illness or disability are the other market drivers.
Pre book Market Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=78699<ype=S
Key Players Operating in Global API Heparin Market
The global API heparin market is fragmented, with presence of large number of small-scale and large-scale companies.
Leading companies operating in the global API heparin market are:
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceutical Industries Ltd.
- Fresenius SE & Co. KGaA
- Sanofi
- Pfizer, Inc.
- LEO Pharma A/S
- Aspen
- Baxter International Inc.
- B. Braun Melsungen AG
- Syntex S.A.
Ask for Discount :
https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=78699
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
